Q4 Earnings Estimate for BrainsWay Issued By Northland Capmk

BrainsWay Ltd. (NASDAQ:BWAY) – Analysts at Northland Capmk upped their Q4 2024 earnings per share estimates for BrainsWay in a note issued to investors on Tuesday, November 12th. Northland Capmk analyst C. Byrnes now forecasts that the company will post earnings per share of $0.02 for the quarter, up from their previous forecast of $0.01. The consensus estimate for BrainsWay’s current full-year earnings is $0.05 per share.

BrainsWay (NASDAQ:BWAY) last posted its quarterly earnings results on Tuesday, November 12th. The company reported $0.04 earnings per share for the quarter, beating analysts’ consensus estimates of $0.01 by $0.03. BrainsWay had a return on equity of 3.52% and a net margin of 3.88%. The firm had revenue of $10.50 million for the quarter, compared to the consensus estimate of $10.07 million. During the same period in the previous year, the business earned ($0.01) earnings per share.

Several other analysts have also weighed in on BWAY. Northland Securities raised their price target on BrainsWay from $11.00 to $12.50 and gave the company an “outperform” rating in a research report on Thursday, October 3rd. HC Wainwright reaffirmed a “buy” rating and issued a $16.00 price target on shares of BrainsWay in a report on Monday, October 21st.

BrainsWay Trading Down 4.3 %

Shares of BWAY opened at $9.12 on Friday. The firm’s 50-day moving average is $9.27 and its two-hundred day moving average is $7.49. BrainsWay has a twelve month low of $4.30 and a twelve month high of $10.98. The firm has a market capitalization of $152.12 million, a P/E ratio of 91.21 and a beta of 1.25.

Institutional Trading of BrainsWay

A number of institutional investors have recently added to or reduced their stakes in BWAY. Acadian Asset Management LLC boosted its holdings in BrainsWay by 583.2% in the 1st quarter. Acadian Asset Management LLC now owns 175,416 shares of the company’s stock worth $923,000 after acquiring an additional 149,740 shares during the period. Virtu Financial LLC purchased a new position in shares of BrainsWay during the 1st quarter valued at approximately $60,000. Rhumbline Advisers grew its position in shares of BrainsWay by 10.3% during the second quarter. Rhumbline Advisers now owns 18,077 shares of the company’s stock worth $110,000 after buying an additional 1,695 shares in the last quarter. Perritt Capital Management Inc bought a new stake in shares of BrainsWay in the second quarter worth $121,000. Finally, Good Life Advisors LLC raised its holdings in BrainsWay by 65.5% in the third quarter. Good Life Advisors LLC now owns 55,800 shares of the company’s stock valued at $516,000 after acquiring an additional 22,080 shares in the last quarter. 30.11% of the stock is owned by hedge funds and other institutional investors.

BrainsWay Company Profile

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.